Literature DB >> 25806173

Is there a third line option after chemotherapy and TKI failure in advanced non-small cell lung cancer?

Jacques De Grève1, Lore Decoster1, David van Brummelen1, Caroline Geers1, Denis Schallier1.   

Abstract

Entities:  

Year:  2012        PMID： 25806173      PMCID： PMC4367571          DOI： 10.3978/j.issn.2218-6751.2012.06.04

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


× No keyword cloud information.
  14 in total

1.  Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Authors:  Rafael Rosell; Enric Carcereny; Radj Gervais; Alain Vergnenegre; Bartomeu Massuti; Enriqueta Felip; Ramon Palmero; Ramon Garcia-Gomez; Cinta Pallares; Jose Miguel Sanchez; Rut Porta; Manuel Cobo; Pilar Garrido; Flavia Longo; Teresa Moran; Amelia Insa; Filippo De Marinis; Romain Corre; Isabel Bover; Alfonso Illiano; Eric Dansin; Javier de Castro; Michele Milella; Noemi Reguart; Giuseppe Altavilla; Ulpiano Jimenez; Mariano Provencio; Miguel Angel Moreno; Josefa Terrasa; Jose Muñoz-Langa; Javier Valdivia; Dolores Isla; Manuel Domine; Olivier Molinier; Julien Mazieres; Nathalie Baize; Rosario Garcia-Campelo; Gilles Robinet; Delvys Rodriguez-Abreu; Guillermo Lopez-Vivanco; Vittorio Gebbia; Lioba Ferrera-Delgado; Pierre Bombaron; Reyes Bernabe; Alessandra Bearz; Angel Artal; Enrico Cortesi; Christian Rolfo; Maria Sanchez-Ronco; Ana Drozdowskyj; Cristina Queralt; Itziar de Aguirre; Jose Luis Ramirez; Jose Javier Sanchez; Miguel Angel Molina; Miquel Taron; Luis Paz-Ares
Journal:  Lancet Oncol       Date:  2012-01-26       Impact factor: 41.316

Review 2.  The role of irreversible HER family inhibition in the treatment of patients with non-small cell lung cancer.

Authors:  Eunice Kwak
Journal:  Oncologist       Date:  2011-10-20

3.  Erlotinib in previously treated non-small-cell lung cancer.

Authors:  Frances A Shepherd; José Rodrigues Pereira; Tudor Ciuleanu; Eng Huat Tan; Vera Hirsh; Sumitra Thongprasert; Daniel Campos; Savitree Maoleekoonpiroj; Michael Smylie; Renato Martins; Maximiliano van Kooten; Mircea Dediu; Brian Findlay; Dongsheng Tu; Dianne Johnston; Andrea Bezjak; Gary Clark; Pedro Santabárbara; Lesley Seymour
Journal:  N Engl J Med       Date:  2005-07-14       Impact factor: 91.245

4.  Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial.

Authors:  Vincent A Miller; Vera Hirsh; Jacques Cadranel; Yuh-Min Chen; Keunchil Park; Sang-We Kim; Caicun Zhou; Wu-Chou Su; Mengzhao Wang; Yan Sun; Dae Seog Heo; Lucio Crino; Eng-Huat Tan; Tsu-Yi Chao; Mehdi Shahidi; Xiuyu Julie Cong; Robert M Lorence; James Chih-Hsin Yang
Journal:  Lancet Oncol       Date:  2012-03-26       Impact factor: 41.316

Review 5.  New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer.

Authors:  Geoffrey R Oxnard; Maria E Arcila; Juliann Chmielecki; Marc Ladanyi; Vincent A Miller; William Pao
Journal:  Clin Cancer Res       Date:  2011-07-20       Impact factor: 12.531

6.  EGFR mutation heterogeneity and the mixed response to EGFR tyrosine kinase inhibitors of lung adenocarcinomas.

Authors:  Zhi-Yong Chen; Wen-Zhao Zhong; Xu-Chao Zhang; Jian Su; Xue-Ning Yang; Zhi-Hong Chen; Jin-Ji Yang; Qing Zhou; Hong-Hong Yan; She-Juan An; Hua-Jun Chen; Ben-Yuan Jiang; Tony S Mok; Yi-Long Wu
Journal:  Oncologist       Date:  2012-06-06

7.  Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu.

Authors:  J De Grève; E Teugels; C Geers; L Decoster; D Galdermans; J De Mey; H Everaert; I Umelo; P In't Veld; D Schallier
Journal:  Lung Cancer       Date:  2012-02-10       Impact factor: 5.705

8.  Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023.

Authors:  Karen Kelly; Kari Chansky; Laurie E Gaspar; Kathy S Albain; James Jett; Yee C Ung; Derick H M Lau; John J Crowley; David R Gandara
Journal:  J Clin Oncol       Date:  2008-03-31       Impact factor: 44.544

9.  Should Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Be Continued beyond Progressive Disease?

Authors:  Young Hak Kim; Akiko Fukuhara; Michiaki Mishima
Journal:  Case Rep Oncol       Date:  2011-09-20

10.  Amplification of CRKL induces transformation and epidermal growth factor receptor inhibitor resistance in human non-small cell lung cancers.

Authors:  Hihu Wing Cheung; Jinyan Du; Jesse S Boehm; Frank He; Barbara A Weir; Xiaoxing Wang; Mohit Butaney; Lecia V Sequist; Biao Luo; Jeffrey A Engelman; David E Root; Matthew Meyerson; Todd R Golub; Pasi A Jänne; William C Hahn
Journal:  Cancer Discov       Date:  2011-10-17       Impact factor: 39.397
View more
  1 in total

1.  Systematic review and meta-analysis of third-line salvage therapy for the treatment of advanced non-small-cell lung cancer: A meta-analysis of randomized controlled trials.

Authors:  Nan Zhang; Nan Guo; Liang Tian; Zhigang Miao
Journal:  Oncotarget       Date:  2018-03-23
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.